Brian Jonas, PhD
Hematology & Oncology · Sacramento, CANPI 1558542209
Payments from drug & device makers
Across 429 payments — averaging $16,908 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3.7M
- Pharmacyclics LLC, An Abbvie Company$1.4M
- Jazz Pharmaceuticals Inc.$979K
- Amgen$505K
- Genentech, Inc.$312K
- Incyte Corporation$85K
- plus $310K from 15 others
Across 3 payments — averaging $956.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2K
- F. Hoffmann-la Roche AG$393
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 239 | $3,664,206 |
| Pharmacyclics LLC, An Abbvie Company | 24 | $1,397,677 |
| Jazz Pharmaceuticals Inc. | 8 | $979,354 |
| Amgen | 6 | $505,010 |
| Genentech, Inc. | 26 | $312,458 |
| Incyte Corporation | 38 | $85,034 |
| Eli Lilly | 4 | $77,597 |
| Gilead | 12 | $57,779 |
| F. Hoffmann-la Roche AG | 11 | $50,751 |
| Novo Nordisk | 1 | $39,493 |
| Bristol Myers Squibb | 7 | $27,702 |
| Daiichi Sankyo Inc. | 28 | $19,401 |
| Genentech USA, Inc. | 7 | $9,787 |
| Rigel Pharmaceuticals, Inc. | 7 | $9,098 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $5,700 |
| Pfizer | 2 | $4,250 |
| E.r. Squibb & Sons, L.L.C. | 2 | $4,249 |
| Servier Pharmaceuticals LLC | 1 | $3,740 |
| Secura Bio, Inc. | 1 | $184 |
| Janssen Scientific Affairs, LLC | 1 | $73 |
| Stemline Therapeutics Inc. | 1 | $17 |
How this compares
$7,253,557 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Sacramento
- Joseph TuscanoSacramento$20.4M
- Jonathan RiessSacramento$9.8M
- Alain AlgaziSan Francisco$119.2M
- David BerzLos Angeles$43.3M
- Jonathan GoldmanSanta Monica$35.7M
- Omid HamidSanta Monica$23.7M
- Nicholas McAndrewLos Angeles$22.9M
- Aditya BardiaSanta Monica$22.1M
- Zev WainbergSanta Monica$19.3M
- Caitlin CostelloSan Diego$16.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.